Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Atai Life Sciences N.V.
(NQ:
ATAI
)
1.300
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Atai Life Sciences N.V.
< Previous
1
2
3
4
Next >
atai Life Sciences to Participate in Upcoming May Investor Conference
May 02, 2023
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
April 28, 2023
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
April 13, 2023
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
March 24, 2023
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
March 06, 2023
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
atai Life Sciences
Via
GlobeNewswire
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
January 26, 2023
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Economy
Exposures
Supply Chain
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
January 09, 2023
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
January 06, 2023
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
December 23, 2022
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
December 19, 2022
From
atai Life Sciences
Via
GlobeNewswire
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
December 16, 2022
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
November 29, 2022
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
November 17, 2022
From
atai Life Sciences
Via
GlobeNewswire
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
November 14, 2022
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Retirement
Exposures
Pension
Product Safety
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update
November 10, 2022
From
atai Life Sciences
Via
GlobeNewswire
Women in Psychedelics Announces atai as Platinum Sponsors
November 04, 2022
From
Women in Psychedelics Network
Via
Business Wire
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences
November 01, 2022
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update
November 01, 2022
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
October 25, 2022
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces R&D Day Agenda
October 20, 2022
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
October 18, 2022
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
October 12, 2022
From
atai Life Sciences
Via
GlobeNewswire
Psychedelic Drugs Prove Their Worth In Clinical Trials
October 11, 2022
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial...
Via
PressReach
Colorado to Vote on Legalizing Psychoactives in November
October 05, 2022
Voters in Colorado will have a say in the legalization of psychedelic drugs this November as an initiative to legalize psilocybin mushrooms and other naturally occurring psychedelics appears on the...
Via
PressReach
Topics
Supply Chain
Exposures
Supply Chain
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
October 05, 2022
A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll...
Via
PressReach
Topics
Cannabis
Exposures
Cannabis
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
October 05, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,...
Via
FinancialNewsMedia
Topics
Cannabis
Exposures
Cannabis
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT
October 05, 2022
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day
October 04, 2022
From
atai Life Sciences
Via
GlobeNewswire
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
September 22, 2022
Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one week after San Francisco officially decriminalized psychedelics, a meeting was held by the City...
Via
PressReach
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.